Slenyto® (PedPRM) was approved by EMA for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient

  • Text size: A A A
  • Circadin
  • Recent news

    • Neurim Pharmaceuticals attends the EPA Congress in Warsaw, Poland, April 7-9, 2019
    • Slenyto (PedPRM) is now also available in UK!
    • Slenyto is now available in Finland
  • Partners